Clinical trials: PD-L1 Expression
Renal Cell Carcinoma
PD-L1 Expression in Japanese Renal Cell Carcinoma Patients
This is a multicenter retrospective study designed to compare overall survival (OS) by PD-L1 expression status in patients with RCC who have received systemic chemotherapy for recurrent or metastatic RCC, to determine whether the…
- Trial name
- NCT03748901
- Where
- Japan
- Volunteers
- 830 people
- Sponsor
- Chugai Pharmaceutical
Non-Small Cell Lung Cancer
PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%
While documented gender differences exist in drug efficacy and safety, men and women are often treated equally due to the absence of gender-specific clinical trials and approvals.
- Trial name
- IFEM (NCT07877584)
- Testing
- Pembrolizumab, Carboplatin (AUC 5), Cisplatin (75 mg/m²)
- Volunteers
- 406 people
- Sponsor
- German Cancer Research Center
Cervical Carcinoma
Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer
Radiotherapy result in tumor cell death by creating an immune potentiation effect, but can also lead to long lasting immune suppression.
- Trial name
- STIRR (NCT06804135)
- Where
- India
- Volunteers
- 110 people
- Sponsor
- Tata Memorial Hospital
Cutaneous Melanoma
Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint Inhibitors
To characterize and quantify immune cells expressing the Interleukine 4 induced gene 1 (IL4I1) immunosuppressive enzyme in the blood and in tissue of melanoma patients (primary tumor, sentinel lymph nodes and cutaneous…
- Trial name
- ENZYMELA (NCT04253080)
- Testing
- Blood sample, Cutaneous melanoma biopsy
- Where
- France
- Volunteers
- 127 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Urinary Bladder Cancer
An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.
The Primary Objective of this observational study is to investigate the prevalence of high PD-L1 expression in Chinese MIUBC patients.
- Trial name
- POLARIS (NCT03433924)
- Where
- 17 sites in China
- Volunteers
- 248 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
99mTc/68Ga Labeled Anti-PD-L1 sdAb in Assessment of PD-L1 Expression in NSCLC
To evaluate the safety, dosimetry and efficacy of 99mTc/68Ga labeled anti-PD-L1 single domian antibody (sdAb) (Product Code Name: 99mTc-NM-01 and 68Ga-NM-01) in the diagnostic imaging PD-L1 expression in Non-Small Cell Lung…
- Trial name
- NCT02978196
- Testing
- Injection of 99mTc-NM-01, Injection of 68Ga-NM-01
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell
A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens
The primary purpose of this non-interventional, multinational study is to assess the feasibility of assessing PD-L1 protein expression on cytological samples as a surrogate for histological samples obtained from participants with…
- Trial name
- NCT03092739
- Testing
- PD-L1 Immunocytochemistry (ICC), PD-L1 Immunohistochemistry (IHC)
- Where
- 8 sites in Czechia, Germany and 4 more
- Volunteers
- 184 people
- Sponsor
- Hoffmann-La Roche
Head and Neck Squamous Cell Carcinoma (HNSCC)
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not…
- Trial name
- NCT06769698
- Testing
- FDC fianlimab+cemiplimab, Cemiplimab
- Where
- 38 sites in United States, Australia and 4 more
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Non-small Cell Lung Cancer Stage IV
Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC
Explore the efficacy and safety of Envafolimab in first line treatment of elderly patients with locally advanced or metastatic non-small cell lung cancer with high PD-L1 expression, view to providing better treatment options for…
- Trial name
- NCT05055167
- Testing
- Envafolimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer
This phase II trial investigates the effect of NBTXR3, radiation therapy, and pembrolizumab in treating patients with head and neck squamous cancer that has come back (recurrent) or has spread to other places in the body…
- Trial name
- NCT04862455
- Testing
- Hafnium Oxide-containing Nanoparticles NBTXR3, Hypofractionated Radiation Therapy, Pembrolizumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Nasopharyngeal Carcinoma
PD-L1 and BRAF Expression in Nasopharyngeal Carcinoma
The prognostic value of programmed death-ligand 1 (PD-L1) and BRAF expression in nasopharyngeal carcinoma (NPC) is not well-defined.
- Trial name
- NCT03989297
- Testing
- Radiation
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Kiang Wu Hospital
Breast Cancer
Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors
This is a single arm window of opportunity trial conducted in patients with early stage triple negative breast tumors to evaluate if treatment with a Poly(ADP-ribose) polymerase (PARP) inhibitor will increase expression of…
- Trial name
- NCT03911453
- Testing
- Rucaparib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Arizona
Non-Small Cell Lung Cancer
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
- Trial name
- HARMONi-7 (NCT06767514)
- Testing
- Ivonescimab Injection, Pembrolizumab Injection
- Where
- 285 sites in United States, Belgium and 15 more
- Volunteers
- 780 people
- Sponsor
- Summit Therapeutics
Colorectal Cancer
Hepatic RFA Increases T Cell Infiltraion and PD-L1 Expression in Primary Colorecatl Cancer
It has been shown that RFA induced systemic tumor antigen-specific T cell responses in human carcinoma. However, there are insufficient studies on the immune modulation of tumor microenviroment (TME) outside of the ablation zone.
- Trial name
- NCT02475889
- Testing
- Hepatic RFA, Primary tumor resection
- Volunteers
- 78 people
- Sponsor
- The First People's Hospital of Changzhou
Non Small Cell Lung Cancer
Consistency of PD-L1 Detecting Method Between E1L3N and 22C3 Monoclonal Antibodies in NSCLC Patients
Evaluated the correlation between the qualitative test results of Xiamen Aide PD-L1 antibody reagent (immunohistochemistry) and the efficacy of Keytruda single-agent therapy, and the research data is used to support the…
- Trial name
- CONFIDENCE (NCT05129462)
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Hunan Province Tumor Hospital
Esophageal Squamous Cell Carcinoma
A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma
This study is a multicentre, randomised, parallel-controlled, open-label, 3 phase clinical trial. The subjects were untreated, unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma with low…
- Trial name
- NCT05919030
- Testing
- Intensity-modulated radiotherapy (IMRT), Tislelizumab, Cisplatin
- Where
- China
- Volunteers
- 155 people
- Sponsor
- Renmin Hospital of Wuhan University
Urothelial Carcinoma
Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma
The purpose of this study is to assess the prevalence of pre-treatment tumor tissue PD-L1 expression in patients diagnosed with advanced urothelial carcinoma.
- Trial name
- PREVAIL (NCT03788746)
- Where
- 58 sites in United States
- Volunteers
- 181 people
- Sponsor
- AstraZeneca
Resectable Non-small Cell Lung Cancer
An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany
The purpose of this observational study is to collect and evaluate real-world data to assess the effectiveness of neoadjuvant nivolumab when given in combination with platinum-based chemotherapy in participants with early-stage…
- Trial name
- NENI (NCT06169956)
- Testing
- Neoadjuvant nivolumab in combination with platinum-based chemotherapy
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Bristol-Myers Squibb
Esophageal Carcinoma, Esophagogastric Junction Carcinoma
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)
In this study, participants with advanced or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the esophagogastric junction (EGJ) that had progressed after first-line…
- Trial name
- NCT02564263
- Testing
- pembrolizumab, paclitaxel, docetaxel
- Volunteers
- 628 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Lymphoblastic Leukemia in Pediatric
Expression of Programmed Death-1 (PD-1) & Programmed Death Ligand-1 (PDL-1) in Acute Lymphoblastic Leukemia in Pediatric
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy in the world. It is a malignant clonal proliferation of lymphoid progenitor cells, but most commonly of the B cell lineage (B ALL). .
- Trial name
- NCT05428111
- Testing
- flow cytometric immunophynotyping
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University